Log in
NASDAQ:AGIO

Agios Pharmaceuticals Stock Forecast, Price & News

$40.07
+0.83 (+2.12 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$38.28
Now: $40.07
$40.13
50-Day Range
$33.42
MA: $36.37
$39.24
52-Week Range
$27.77
Now: $40.07
$56.74
Volume713,950 shs
Average Volume849,216 shs
Market Capitalization$2.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.85
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Read More
Agios Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGIO
CUSIPN/A
Phone617-649-8600
Employees536

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$117.91 million
Book Value$10.88 per share

Profitability

Net Income$-411,470,000.00
Net Margins-182.49%

Miscellaneous

Market Cap$2.77 billion
Next Earnings Date11/5/2020 (Confirmed)
OptionableOptionable
$40.07
+0.83 (+2.12 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

How has Agios Pharmaceuticals' stock been impacted by COVID-19?

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AGIO stock has decreased by 2.0% and is now trading at $40.07.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Agios Pharmaceuticals?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Agios Pharmaceuticals
.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Agios Pharmaceuticals
.

How can I listen to Agios Pharmaceuticals' earnings call?

Agios Pharmaceuticals will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its earnings results on Thursday, July, 30th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.36) by $0.05. The biopharmaceutical company earned $37.30 million during the quarter, compared to analyst estimates of $37.17 million. Agios Pharmaceuticals had a negative net margin of 182.49% and a negative return on equity of 59.71%. The firm's quarterly revenue was up 42.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.87) EPS.
View Agios Pharmaceuticals' earnings history
.

What price target have analysts set for AGIO?

13 brokerages have issued 1 year price targets for Agios Pharmaceuticals' shares. Their forecasts range from $46.00 to $82.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $68.00 in the next twelve months. This suggests a possible upside of 69.7% from the stock's current price.
View analysts' price targets for Agios Pharmaceuticals
.

Are investors shorting Agios Pharmaceuticals?

Agios Pharmaceuticals saw a increase in short interest in September. As of September 30th, there was short interest totaling 6,930,000 shares, an increase of 14.7% from the September 15th total of 6,040,000 shares. Based on an average daily trading volume, of 596,200 shares, the days-to-cover ratio is presently 11.6 days.
View Agios Pharmaceuticals' Short Interest
.

Who are some of Agios Pharmaceuticals' key competitors?

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the following people:
  • Dr. Jacqualyn A. Fouse, CEO & Director (Age 59, Pay $1.25M)
  • Mr. Jonathan Biller J.D., CFO and Head of Legal & Corp. Affairs (Age 56, Pay $150.52k)
  • Dr. Scott A. Biller, Strategic Advisor (Age 64, Pay $687.56k)
  • Dr. Christopher J. Bowden, Chief Medical Officer (Age 59, Pay $701.63k)
  • Dr. Lewis Clayton Cantley, Co-Founder & Member of Scientific Advisory Board (Age 71)
  • Dr. Tak Wah Mak, Co-Founder & Member of Scientific Advisory Board (Age 74)
  • Dr. Craig B. Thompson, Co-Founder & Chairman of Scientific Advisory Board (Age 67)
  • Dr. Shin-San Su Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 64)
  • Ms. Carman Alenson, Principal Accounting Officer and VP of Accounting, Treasury & Tax
  • Dr. Clive Patience, Exec. VP of Technical Operations

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.55%), Peregrine Capital Management LLC (0.24%), BNP Paribas Arbitrage SA (0.18%), State of New Jersey Common Pension Fund D (0.08%), WINTON GROUP Ltd (0.08%) and DekaBank Deutsche Girozentrale (0.05%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, Jacqualyn A Fouse, Scott Biller and Steven L Hoerter.
View institutional ownership trends for Agios Pharmaceuticals
.

Which institutional investors are selling Agios Pharmaceuticals stock?

AGIO stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Peregrine Capital Management LLC, and Parallel Advisors LLC. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, and Christopher Bowden.
View insider buying and selling activity for Agios Pharmaceuticals
.

Which institutional investors are buying Agios Pharmaceuticals stock?

AGIO stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., DekaBank Deutsche Girozentrale, WINTON GROUP Ltd, State of New Jersey Common Pension Fund D, Arthur M. Cohen & Associates LLC, Pacer Advisors Inc., and Nisa Investment Advisors LLC. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse.
View insider buying and selling activity for Agios Pharmaceuticals
.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $40.07.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $2.77 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 536 workers across the globe.

What is Agios Pharmaceuticals' official website?

The official website for Agios Pharmaceuticals is www.agios.com.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.